Milan, Italy (August 27, 2024)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its attendance at 2024 Euretina Innovation Spotlight and Congress.

The event will be held September 18-22, 2024 in Barcelona, Spain. Marco Ferroni, Chief Executive Officer, and Beatrice Belgio, Lead Scientist/Head of drug delivery, will be attending the congress with the aim to cement current relationships and establish new ones with physicians and strategic partners, in order to implement MgShell Early Adopters Engagement Plan by starting preliminary conversations with vitreoretinal specialists.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.